CELLECTAR BIOSCIENCES INC (CLRB) Stock News

USA - Nasdaq - NASDAQ:CLRB - US15117F8804 - Common Stock

4.02 USD

+0.1 (+2.55%)

Last: 12/10/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CLRB Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

4 months ago - By: The Motley Fool

Cellectar Cuts Q2 Losses and Expenses

4 months ago - By: Benzinga

A Peek at Cellectar Biosciences's Future Earnings

a month ago - By: Benzinga - Mentions: ECC VINP INV VTGN ...

Earnings Scheduled For November 13, 2025

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

2 months ago - By: Stocktwits - Mentions: VTI DFAS F

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

4 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

5 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

5 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option